Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 122

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 122
---
ems equitable, adjust any or all of (1) the number and type of shares subject to the 2023 Omnibus Plan and which may, after the event, be made the subject of awards; (2) the number and type of shares of common stock subject to outstanding awards; (3) the grant, purchase, or exercise price with respect to any award; and (4) the performance goals of an award. In any such case, the Administrator may also provide for a cash payment to the holder of an outstanding award in exchange for the cancellation of all or a portion of the award, subject to the terms of the 2023 Omnibus Plan.

The Administrator may, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, authorize the issuance or assumption of awards upon terms and conditions we deem appropriate without affecting the number of shares of common stock otherwise reserved or available under the 2023 Omnibus Plan.

Change of Control

Upon a change of control (as defined in the 2023 Omnibus Plan), the successor or surviving corporation may agree to assume some or all outstanding awards or replace them with the same type of award with similar terms and conditions, without the consent of any participant, subject to the following requirements:

| ● | Each                                                                                                                                       
 award that is assumed must be appropriately adjusted, immediately after such change of control, to apply to the number and class           
 of securities that would have been issuable to a participant upon the consummation of such change of control had the award been exercised, 
 vested, or earned immediately prior to such change of control, and other appropriate adjustment to the terms and conditions of the         
 award may be made.                                                                                                                         |
| ● | If                                                                                                                                         
 the securities to which the awards relate after the change of control are not listed and traded on a national securities exchange,         
 then (a) each participant must be provided the option to elect to receive, in lieu of the issuance of such securities, cash in an          
 amount equal to the fair value of the securities that would have otherwise been issued, and (b) no reduction may be taken to reflect       
 a discount for lack of marketability, minority, or any similar consideration, for purposes of determining the fair value of such           
 securities.                                                                                                                                |
| ● | If                                                                                                                                         
 a participant is terminated from employment without cause, or due to death or disability, or the participant resigns employment for        
 good reason (as defined in any award or other agreement between the participant and our company or an